Wu CE, Chang CF, Huang CY, et al. - Researchers retrospectively analyzed clinical results as well as safety of afatinib treatment in epidermal growth factor receptor (EGFR)-mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC) patients with performance status (PS ≥ 2). They retrospectively studied data for 62 patients who were managed at Linkou Chang Gung Memorial Hospital from January 2010 to August 2019. Until February 2020, the objective response rate, disease control rate, median progression-free survival (PFS), and overall survival (OS) were 58.1% (36/62), 69.4% (43/62), 8.8 months, and 12.9 months, respectively. Findings in the current cohort showed acceptable efficacy as well as safety of afatinib. The results of this study offered evidence to support afatinib administration as a first-line therapy in EGFRm+ NSCLC patients with poor PS.